Navigation Links
MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
Date:7/22/2013

IRVINGTON, N.Y., July 22, 2013 /PRNewswire/ -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, presented at the 8th World Congress of Melanoma held in Hamburg, Germany, on July 19, 2013, to a well-attended room.    

(Logo: http://photos.prnewswire.com/prnh/20130103/NY36051LOGO)

The symposium, led by Axel Hauschild, MD, PhD, Professor and Head of the Interdisciplinary Skin Cancer Center at the Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany, and by Andreas Blum MD, PhD, Associate Professor of Dermatology at the Medical University of Tuebingen, Germany, and Public, Private and Teaching Practice Dermatology, Konstanz, Germany, focused on mole management and incorporating MelaFind® technology into skin examinations. A panel on "Managing Melanocytic Nevi: How it's Done Today & MelaFind®'s Place in This World," was led by Dr. Blum, followed by an open discussion led by Dr. Hauschild on "Detecting Early Melanomas: MelaFind® Clinical Studies, International Perspectives on Mole Management 2013 & Beyond."

According to data presented by Dr. Hauschild, the detection, diagnosis and management of melanoma by dermatologists improves when using the information generated by MelaFind®. "The additional, objective information and images of a lesion 2.5 mm below the skin surface that MelaFind® offers, when combined with the clinical expertise of dermatologists, leads to a clinically significant increase of thin melanomas detected at the earliest, most curable stage of the disease," said Dr. Hauschild.  "Early detection or rule out is the first step in proper melanoma management and the objective analytical information from MelaFind® clearly helps."

"As leading dermatologists will tell you, survival rate for melanoma significantly improves when detected at its earliest stages and the additional clinical information provided by MelaFind®, as the only optical diagnostic tool that sees 2.5 mm below the skin surface, helps dermatologists effectively find melanomas when they are most curable," said Robert Coradini, Interim CEO for MELA Sciences. "MelaFind® is being successfully implemented in dermatologists' offices across Germany and the United States, and we are pleased to show our research at the World Congress to raise awareness of MelaFind® as the new standard of care for melanoma detection and management." 

MelaFind® has been recognized by the Cleveland Clinic as a Top 10 Medical Innovation for 2013. Consumers can learn more about the device or locate a dermatologist with MelaFind® in their area by visiting www.melafind.com.

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind® and its further design and development.  MelaFind® is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind® has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind® has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes," "predicts" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"). Factors that might cause such a difference include whether MelaFind® achieves market acceptance. Given the uncertainties affecting companies in the medical device industry such as the Company, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The Company urges you to carefully review and consider the disclosures found in its filings with the SEC which are available at www.sec.gov and www.melasciences.com.


'/>"/>
SOURCE MELA Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference
2. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
3. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
4. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
5. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
6. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
7. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
8. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
9. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
10. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):